key: cord-0851887-1tzc43q3
authors: Alshaqaq, Ali; Al Abadi, Abdulnaser; Altheaby, Abdulrahman; Bukhari, Mohammed A.; Nasrallah, Basil; Alamoudi, Alaa; Arabi, Ziad; Alhejaili, Fayez; Saad, Khalid Bin; Busbaih, Ahmed; Idris, Mohammed Abdelrahim; Askandarani, Sumayah; AlBugami, Meteb M.; Alotaibi, Fahad E.; Hamawi, Khaled; Akkari, Khalid Bel’eed
title: Coronavirus Disease 2019 and Kidney Transplantation in Saudi Arabia: Outcomes and Future Opportunities
date: 2021-06-04
journal: Ann Transplant
DOI: 10.12659/aot.931832
sha: b72856bf1fc457a2023f26eef14456604b1132f2
doc_id: 851887
cord_uid: 1tzc43q3

BACKGROUND: Kidney transplant services all over the world were severely impacted by the coronavirus disease 2019 pandemic. The optimum management of kidney transplant recipients with coronavirus disease 2019 remains uncertain. MATERIAL/METHODS: We conducted a multicenter cohort study of kidney transplant recipients with coronavirus disease 2019 infection in Saudi Arabia. Multivariable Cox regression analysis was used to study predictors of graft and patient outcomes at 28 days after coronavirus disease 2019 diagnosis. RESULTS: We included 130 kidney transplant recipients, with a mean age of 48.7(±14.4) years. Fifty-nine patients were managed at home with daily follow-up utilizing a dedicated clinic, while 71 (54.6%) required hospital admission. Acute kidney injury occurred in 35 (26.9%) patients. Secondary infections occurred in 38 (29.2%) patients. SARS-CoV-2 antibodies testing was carried out in 84 patients, of whom 70 tested positive for IgG and/or IgM. Fourteen patients died (10.8%). A multivariable Cox regression analysis showed that age, creatinine at presentation, acute kidney injury, and use of azithromycin were significantly associated with worse patient survival. Graft loss was associated with requiring renal replacement therapy and development of secondary infections. CONCLUSIONS: Despite kidney transplant recipients with coronavirus disease 2019 infection having higher rate of hospital admission and mortality compared to the general population, a significant number of them can be managed using a telemedicine clinic. Most kidney transplant patients seem to mount an antibody response following coronavirus disease 2019 infection, and it remains to be seen if they will have a similar response to the incoming vaccines.

Coronavirus disease 2019 (COVID-19) is an emerging disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first discovered in China in late 2019. This viral infection has spread all over the globe and was declared a pandemic by WHO in March 2020. By April 2021, SARS-CoV-2 had infected almost 145 million persons, causing almost 3 million deaths worldwide. During the same period, Saudi Arabia (SA) reported a total of 409 038 cases, with a 1.8% fatality rate [1] . In response to the COVID-19 pandemic, SA implemented lockdown of public and private services and established nationwide restrictions on population movement. As a result, most elective organ transplant activities were halted for several months.

Immunocompromised patients are more vulnerable to viral infections and their devastating consequences. Not infrequently, kidney transplant patients have other comorbidities, such as diabetes, advanced age, pulmonary diseases, ischemic heart disease, and obesity, which are additional risk factors for acquisition and progression of infection [2] . Telemedicine can help to screen and triage suspected or confirmed COVID-19 cases that need hospitalization while minimizing exposure to patients and health care providers.

Due to its novelty, several observations have emerged from cohort studies addressing the clinical presentation and outcomes of COVID-19 in kidney transplant recipients (KTRs). However, there remain uncertainties about the optimal strategies for use of antiviral and immune-modulating agents, and management of immunosuppression (IS) [3] . Similarly, limited data are available about the duration of SARS-CoV-2 viral shedding, period of isolation required, and the immune response in this population [4] .

In this multicenter study of kidney transplant patients with COVID-19, we investigated the clinical outcomes, duration of viral shedding, and immune response to SARS-CoV-2. The aim of this study was to enhance the knowledge in the transplant community regarding this novel disease.

This was a retrospective observational cohort study that was carried out in 5 transplant centers in SA. Inclusion criteria included all adult patient (age >16 years) KTRs with a positive SARS-CoV-2 test result by real-time reverse transcriptase-polymerase chain reaction (rt-PCR) between March 1 and August 31, 2020. The study was approved by the institutional review boards of all participating centers.

According to the national risk stratification for SARS-CoV-2 infection [5] , patients with mild to moderate symptoms were managed as outpatients. We created a dedicated COVID-19 clinic which consisted of a transplant nephrologist and a clinical coordinator (Figure 1) . Patients with confirmed infection that did not require hospital admission upon initial assessment were asked to self-isolate at home. A hotline for direct communication with the clinical coordinator was established, and patients were provided with pulse oximeters. Patients were asked to monitor their symptoms, temperature, and oxygen saturation. Symptoms like dyspnea, persistent fever, vomiting or diarrhea with inability to tolerate oral intake, as well as drop in the oxygen saturation below 94%, were an indication to visit the emergency department. Patients were contacted daily by the coordinators for updates. Laboratory and radiological investigations were done through a designated ambulatory clinic. A kidney transplant recipient with close contact with a COVID-19 case within the family or in the community, but with no symptoms, was instructed to self-isolate and monitor symptoms. Such patients were tested for SARS-CoV-2 at day 5 and day 14 from the last exposure to the index case.

More severe cases were admitted to the hospital, where they were treated by a specific protocol that provided recommendations on IS management, in addition to the national guidelines for COVID-19 treatment, which included recommendations for antiviral and antibacterial therapies, anticoagulation, and other therapeutic interventions like the use of tocilizumab and convalescent plasma [5] .

We collected data on baseline patient characteristics, symptoms, laboratory, radiological findings at presentation, concomitant infections, management of IS, other therapeutic interventions, and duration of viral shedding, as well as ICU admissions, respiratory support, AKI, requirement of renal replacement therapy, and 28-day graft and patient outcomes.

SARS-CoV-2 antibodies (IgG and IgM) were studied in 84 patients using rapid membrane-based lateral flow immunoassay (PRIMA lab SA, Switzerland). Data were extracted onto a unified data collection template from the electronic medical records.

Descriptive results are presented as mean±standard deviation for normally distributed data, or median with interquartile range for non-normally distributed data. Numbers and percentages are reported for all qualitative variables. Bivariate analysis was used to explore the correlation of clinical and laboratory characteristics with the overall patient and graft survival using the Cox proportional hazard model. All the statistically significant predictors in the bivariate analysis and clinically important variables were entered in a multiple Cox proportional hazard model. The final model was assessed using the goodness-of-fit test to see if the model fit the data. Adjusted hazard odds ratio and 95% confidence interval were reported for each independent factor. Two-sided P value <0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 24.0.

During the study period, the participating centers identified 130 KTRs with a diagnosis of COVID-19 among their patients. Demographics, comorbidities, and baseline IS are listed in 

Clinical features at presentation, including laboratory results and radiological findings, are summarized in 

Abnormal chest X-ray 43 (33.1%)

White blood cell count ×10 9 /L a 5.75±2.39 A multivariable Cox regression analysis using variables meeting significance in a bivariate analysis showed that age, creatinine level at presentation, development of AKI, and use of azithromycin were significantly associated with worse patient survival ( Table 4) . Graft loss was associated with requiring renal replacement therapy and development of secondary infections ( Table 5 ).

We report the clinical outcomes of 130 KTRs with COVID-19 in 5 transplant centers across SA. Our study showed a 10.8% mortality rate among kidney transplant patients with SARS-CoV-2 infection, with 0.77% graft loss.

The COVID-19 pandemic presents a major challenge to health care systems worldwide. Appropriate and timely provision of care is important when dealing with high-risk patients such as KTRs. Given the large number of infected people and with limited hospital resources, structured outpatient management of KTRs with COVOD-19 via telemedicine appears to be a reasonable approach [6, 7] . Clinical presentation was similar to that in the general population [8] [9] [10] KTRs with COVID-19 present a clinical challenge in the absence of evidence of effective interventions in this immunesuppressed group, often with multiple comorbidities [12] . The optimal management of immunosuppressive medication in KTRs with COVID-19 has not yet been established, and the decision to adjust immunosuppressive medications should consider patient's age, time since transplant, and the severity of COVID-19 disease and associated comorbidities [3] . Generally, we opted to lower MMF, and to a lesser extent tacrolimus doses, and used corticosteroids as per the evidence that developed over time [13] . So far, there is no strong evidence to guide adjustment of immunosuppressive medication in COVID-19 patients and most of the practice is based on expert's opinion and small studies [14, 15] . We documented no biopsy-proven acute rejection after minimizing immunosuppressive medication in this cohort.

The small number of patients where other therapeutic interventions were used -favipiravir in 26 (20%), hydroxychloroquine in 15 (11.5%), and azithromycin in 40 (30.8%), and tocilizumab, and convalescent plasma in 14 (10.8%) -reflects the degree of uncertainty that prevailed at the start of the pandemic. However, therapeutic options for COVID-19 and its effect on survival have changed since the beginning of the pandemic. For example, azithromycin and hydroxychloroquine were not found to be associated with mortality benefit or other clinical outcomes [16, 17] . Antivirals, which block replication, and antiinflammatories like tocilizumab, are considered part of treatment in most of treatment protocols [5] . Recent reports from the RECOVERY and REMAP-CAP trials showed that treatment with tocilizumab led to lower mortality across patients with different disease severities [18, 19] . Two studies using a hamster model of SARS-CoV-2 infection have shown a modest antiviral effect of favipiravir [20, 21] . In a retrospective study from 2 hospitals in SA, use of favipiravir was associated with accelerated discharge rate and less progression to mechanical ventilation, but no overall mortality benefits [22] .

The threshold to admit KTRs with COVID-19 to hospital or ICU changed as the experience in treating COVID-19 developed in the first few months. In our cohort, of the 71 patients admitted to hospital, 28 (21.5%) needed ICU admission, of whom 18 (13.8%) required intubation and mechanical ventilation. In another single-center study from SA included 44 KTRs; 70% required admission to hospital, with 16% needing ICU, and 1 patient required mechanical ventilation [23] . Another study of 53 kidney transplant patients with COVID-19 reported that 22% required ICU care and 90% of them required mechanical ventilation [24] .

Several mechanisms have been postulated for development of AKI in COVID-19 patients, including multiorgan dysfunction syndrome, SARS-CoV-2 direct kidney infection [25] , infectionrelated generalized mitochondrial failure, and cytokine storm syndrome. We used acute kidney injury network criteria to define AKI in our cohort. Thirty-five (26.9%) patients had AKI, and this was associated with poor patient survival. Eight (6.2%) patients required dialysis compared to 21% in the study by Akalin et al [26] and 31% in the TANGO study [27] . In our multivariable Cox regression analysis, requirement of renal replacement therapy was associated with poor graft survival.

Concomitant infections with COVID-19 disease are not uncommon in immunocompromised patients. In our study, bacterial infections occurred in 29 (22.3%) patients, cytomegalovirus (CMV) viremia in 6 (4.6%) patients, and invasive aspergillosis infection in 3 (2.3%) patients. A higher incidence (48%) of bacterial infections was reported by Lubetzky et al [6] . In a meta-analysis of 11 studies, the risk of invasive aspergillosis was greater in KTRs who had post-transplant bacterial infection, respiratory viral infection, and CMV infection or disease [28] . We found that 2 out the 6 patients who had CMV viremia were treated with tocilizumab. Reactivation of CMV with IL-6 antagonist therapy, like tocilizumab, is a potential concern. Khatib et al reported a case of life-threatening lower gastrointestinal bleeding secondary to CMV colitis in a patient with COVID 19 pneumonia who was treated with tocilizumab [29] . Development of secondary infections was significantly associated with poor graft survival in our study. A high index of suspicion for secondary infection with early diagnosis and administration of antimicrobial therapy should be considered when dealing with SARS-CoV 2 infection in kidney transplant patients.

Seventy out of 84 patients in our study tested positive when SARS-CoV-2 testing was repeated at mean of 17.2 days. The mean time to achieve negative PCR was 31.5 (±16.2) days. In a study of 40 KTRs hospitalized for COVID-19, one-quarter of their patients were shedding the virus at 30 days at a median follow-up of 53 days [30] . Another study, of 10 KTRs, found the mean duration of viral shedding was 28.4 (±9.3) days as compared to 12.2 (±4.6) days in their family members [31] . Previous studies involving renal transplant patients showed prolonged shedding of other respiratory viruses, which ranged from 6 to 44 days [32] . The duration of viral shedding does not necessarily correlate with infectivity. Current data indicates that risk of infection decreased to zero after 10 days of symptoms in mild to moderate cases and after about 15-20 days in immunocompromised or critically ill patients [33] . The Centers for Disease Control and Prevention currently recommends 20 days of isolation from symptom onset for immunocompromised patients or those with critical illnesses [34] . This results in decreasing the quarantine period, particularly for asymptomatic patients and improves overall patient care.

The utility of measuring antibody response to SARS-CoV-2 remains uncertain, and its usefulness for epidemiological and infection control purposes is yet to be determined. Antibody tests were carried out in 84 of our patients, of whom 83% had evidence of humoral response. Similarly, a study of 40 KTRs by Benotmane and colleagues found that 90% had positive antibodies against SARS-CoV-2 [30] . Another study of 18 KTRs at Mount Sinai Hospitals, 16 patients showed positive anti-SARS-CoV-2 IgM or IgG titers [35] . Together, these initial results indicate that immunocompromised kidney transplant patients seem to have an excellent humoral response to SARS-CoV-2. It remains to be seen, however, if KTRs will show a similar response to any of the current COVID-19 vaccines.

Limitations of this work include its retrospective methodology, small number of patients in some of the participating centers, and short median follow-up time, in addition to the complexity incurred by the evolving clinical evidence at the time of the study.

Our study showed that SARS-CoV-2 infection remains a serious infection with significant mortality. A significant proportion of KTRs with SARS-CoV-2 infections do not require hospital admission and can be managed using a telemedicine clinic. Moving forward, transplant health care providers should focus on adopting telehealth technology and infrastructure to provide the best care for their high-risk patients. Most kidney transplant patients seem to mount an antibody response following SARS-CoV-2 infection, and it remains to be seen if they will have a similar response to the upcoming vaccines. Until results of further research on SARS-CoV-2 infection in transplant patients are available, lowering the burden of immunosuppression remains its cornerstone, with other lines of management continuing to extrapolate from that in the general population.

COVID-19 Dashboard

An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants

C4 article: Implications of COVID-19 in transplantation

Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: When is it safe to discontinue isolation?

Diseases 19 (COVID-19) guidelines

Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: A report of consecutive cases from a New York City transplant center

The role of telemedicine in kidney transplantation: Opportunities and challenges

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State

Clinical characteristics of Coronavirus disease 2019 in China

Outpatient management of the kidney transplant recipient during the SARS-CoV-2 virus pandemic

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study

Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis

Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients

Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients

Effect of hydroxychloroquine in hospitalized patients with Covid-19

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): Preliminary results of a randomised, controlled, open-label, platform trial

Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of effect for hydroxychloroquine

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: A retrospective study with propensity score matching sensitivity analysis

Coronavirus disease-19: Disease severity and outcomes of solid organ transplant recipients: Different spectrums of disease in different populations?: Disease severity and outcomes of solid organ transplant recipients different spectrum of disease in different populations?

Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target

COVID-19 and kidney transplantation

COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium

Risk factors for the development of invasive aspergillosis after kidney transplantation: Systematic review and meta-analysis

Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19

In-depth virological assessment of kidney transplant recipients with COVID-19

Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: A summary of 10 confirmed cases in Wuhan, China

Prolonged respiratory viral shedding in transplant patients

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19

Duration of Isolation and Precautions for Adults with COVID-19

Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients